Previous research has shown that BLC can provide improved detection rates, mainly for high-risk disease and invasive tumors.
Urothelial Carcinoma Diagnostics
This newly developed assay can assess the genomic profile of ctDNA in patients with advanced UC.
Dr. Lotan discusses risk stratification and outlines the next steps for integrating Cxbladder Triage into clinical practice.
Dr. Lotan describes the design and key findings of the STRATA trial using Cxbladder Triage for patients with microhematuria.
Dr. Jensen highlights the single-arm trial design and TOMBOLA's use of ctDNA.
ctDNA testing may help identify patients with bladder cancer who would benefit from early post-cystectomy immunotherapy.
Drs. Gupta and Kohlmann focus on the prevalence of pathogenic variants in the urethra, upper tract, and bladder.
Drs. Gupta and Kohlmann discuss why comprehensive germline testing is crucial for accurate diagnosis and treatment of UTUC.
Dr. Sonpavde shares his thoughts on first-line therapy for aUC, including trials like CheckMate 274, AMBASSADOR, and NIAGRA.
The genetic basis of HER2 overexpression other than ERBB2 amplification in UC is not well understood.
WGS-based ctDNA detection offered a median lead time of 131 days over radiographic imaging.
Conference Coverage
Noah Hahn, MD, gives an overview of durvalumab with intravesical gemcitabine and docetaxel for BCG-unresponsive NMIBC.
Dr. Daniel Joyce gives an overview of his study that examined the use of necrosis as a prognostic indicator for mRCC.
Drs. Karine Tawagi and Samantha Armstrong expand on the prostate cancer discussions of note, including TALAPRO-2.
Drs. Tawagi and Armstrong provide detail and discussion on the bladder cancer research from the 2025 ASCO GU meeting.
Drs. Tawagi and Armstrong recap the hottest topics in kidney cancer research from the 2025 ASCO GU Cancers Symposium.
Dr. Sonpavde provides an update on the latest analysis from the phase 3 global study of EV in combination with pembro.